NFX Nuformix plc
Nuformix plc, together with its subsidiary, Nuformix Technologies Limited, operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. The company develops NXP001, which is in the Phase 1 stage for use in oncology supportive care; NXP002, which is in the pre-clinical stage for the treatment of idiopathic pulmonary fibrosis; and NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology. It has a licensing agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc is based in London, the United Kingdom.…
Industry Peers
BiotechnologyKey Statistics
About Nuformix (LON: NFX)
›
Nuformix (LON: NFX) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 3 employees.
The shares were at 0.0650 GBp on 19 November 2026, down 76.8% over 52 weeks. Its 52-week range is 0.0600 GBp to 0.4000 GBp: the price is 83.8% below the high and 8.3% above the low.
Its market capitalisation is 1.70M GBP.
Nuformix reports return on equity of -86.4% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 930.28K GBP. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.